Diagnostic and prognostic value of serum NfL and p-Tau
Aged
Alzheimer Disease
/ diagnosis
Biomarkers
/ blood
Case-Control Studies
Cross-Sectional Studies
Diagnosis, Differential
Female
Frontotemporal Lobar Degeneration
/ blood
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Motor Cortex
/ physiology
Neurofilament Proteins
/ blood
Neuroimaging
Phosphorylation
Prognosis
Retrospective Studies
Transcranial Magnetic Stimulation
tau Proteins
/ blood
Journal
Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
13
04
2020
revised:
28
05
2020
accepted:
03
06
2020
pubmed:
3
7
2020
medline:
26
1
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
To assess the diagnostic and prognostic value of serum neurofilament light (NfL) and serum phospho-Tau In this retrospective study, performed on 417 participants, we analysed serum NfL and p-Tau We observed significantly higher levels of serum NfL in patients with FTLD syndromes, compared with healthy controls, and lower levels of p-Tau The assessment of serum NfL and p-Tau
Identifiants
pubmed: 32611664
pii: jnnp-2020-323487
doi: 10.1136/jnnp-2020-323487
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
neurofilament protein L
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
960-967Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper.